Compare Natera Inc. Common Stock (NTRA) vs SanDisk (SNDK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs SanDisk — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while SanDisk trades at $1,340.01 (market cap $202.82B). The key difference: SanDisk is far larger — about 3.6× Natera Inc. Common Stock's market cap, and SanDisk is more actively traded (7,345,106 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and SanDisk for 10 Days on average.
| NTRA | SNDK | |
|---|---|---|
Market Cap | $57.03B | $202.82B |
Volume | 1,131,157 | 7,345,106 |
Sector | Health | Technology |
52-Week High | $425.64 | $2.34K |
52-Week Low | $179.42 | $140.16 |
Typical Hold Time | 0 Days | 10 Days |
Enterprise Value | $56.18B | $198.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SNDK trades at $1,482.33, down 0.34% amid sector-wide pressure from Chinese competition concerns. The stock shows bearish technical signals with strong analyst support (87.5% buy rating) and a $2,160 consensus price target. Recent earnings beats contrast with current negative profitability, though 2026 projections show dramatic improvement to $11.4B net income. The company maintains strong balance sheet fundamentals with $1.48B cash and manageable debt levels.
SNDK presents a compelling risk-reward opportunity with significant upside potential to analyst targets, though near-term volatility from memory sector headwinds persists. The company's AI memory positioning and projected 2026 profitability growth support long-term bullish thesis, while current technical weakness may offer attractive entry points for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About SanDisk
Sandisk is a semiconductor memory company specializing in NAND flash technology. Its storage products support consumer devices, enterprise systems, and cloud and AI infrastructure.
Read more on SNDK →
